Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
 
Status Schedule affected by COVID-19
Process STA 2018
ID number 1483

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
13 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
28 January 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of roxadustat for treating anaemia in people with chronic kidney disease ID1483. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. On receiving updated regulatory timing information from the company that markets roxadustat, NICE has agreed that holding a scoping exercise at this time is not appropriate. Consequently, the scoping workshop arranged for the 17 March 20 will be cancelled. We apologise for any inconvenience this may cause. The workshop and consultation will be rescheduled to take place later in 2020. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk)

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance